NCT07659795Phase 2Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants150Estimated

Source updated2026-09-25Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-07 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Colorectal Cancer

Treatments or interventions studied

VS-7375Drug
cetuximabDrug
panitumumabDrug
Cetuximab + mFOLFOX6Drug

Primary outcomes · main study measures

Read the study measures

measure: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only; description: Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR); timeFrame: 6 months; measure: To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC; description: Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations; timeFrame: 6 months; measure: To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC; description: Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations; timeFrame: 6 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history